US226A
(en)
|
|
1837-06-03 |
|
Samuel goss |
US541606A
(en)
|
|
1895-06-25 |
|
Sealed package |
US7709A
(en)
|
|
1850-10-08 |
Chas S Gaylord |
Improved spring-grapple
|
EP0090505B1
(en)
|
1982-03-03 |
1990-08-08 |
Genentech, Inc. |
Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
US4978672A
(en)
|
1986-03-07 |
1990-12-18 |
Ciba-Geigy Corporation |
Alpha-heterocyclc substituted tolunitriles
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
DE3785186T2
(de)
|
1986-09-02 |
1993-07-15 |
Enzon Lab Inc |
Bindungsmolekuele mit einzelpolypeptidkette.
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
EP0296122B1
(en)
|
1987-06-17 |
1993-09-29 |
Sandoz Ag |
Cyclosporins and their use as pharmaceuticals
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
US20030206899A1
(en)
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
ATE463573T1
(de)
|
1991-12-02 |
2010-04-15 |
Medimmune Ltd |
Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
|
ATE498632T1
(de)
|
1992-10-28 |
2011-03-15 |
Genentech Inc |
Verwendung von vaskulären endothelwachstumsfaktor-antagonisten
|
EP1005870B1
(en)
|
1992-11-13 |
2009-01-21 |
Biogen Idec Inc. |
Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
DK0672142T3
(da)
|
1992-12-04 |
2001-06-18 |
Medical Res Council |
Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
US7138500B1
(en)
|
1993-05-07 |
2006-11-21 |
Immunex Corporation |
Antibodies to human 4-1BB
|
IL108501A
(en)
|
1994-01-31 |
1998-10-30 |
Mor Research Applic Ltd |
Antibodies and pharmaceutical compositions containing them
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5688690A
(en)
|
1994-09-16 |
1997-11-18 |
The Wistar Institute Of Anatomy And Biology |
Human cytotoxic lymphocyte signal transduction surface protein (P38) and monoclonal antibodies thereto
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
AUPO591797A0
(en)
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
CN1241944C
(zh)
|
1995-09-11 |
2006-02-15 |
协和发酵工业株式会社 |
抗人白介素-5受体α链的抗体
|
JP2002514895A
(ja)
*
|
1995-09-28 |
2002-05-21 |
アレクション、ファーマスーティカルズ、インコーポレーテッド |
ブタ細胞相互作用タンパク質
|
US7357927B2
(en)
|
1996-03-12 |
2008-04-15 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
EP1947183B1
(en)
|
1996-08-16 |
2013-07-17 |
Merck Sharp & Dohme Corp. |
Mammalian cell surface antigens; related reagents
|
US6140076A
(en)
|
1996-12-06 |
2000-10-31 |
Schering Corporation |
Ig superfamily `dlair` receptors expressed in monocytes
|
US20060280140A9
(en)
*
|
1997-02-06 |
2006-12-14 |
Mahany Ronald L |
LOWER POWER WIRELESS BEACONING NETWORK SUPPORTING PROXIMAL FORMATION, SEPARATION AND REFORMATION OF WIRELESS LOCAL AREA NETWORKS (LAN's), AS TERMINALS MOVE IN AND OUT RANGE OF ONE ANOTHER
|
US6972323B1
(en)
|
1997-04-01 |
2005-12-06 |
Sankyo Company, Limited |
Anti-Fas antibodies
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
PT973804E
(pt)
|
1997-04-07 |
2007-03-30 |
Genentech Inc |
Anticorpos anti-vegf
|
KR100870353B1
(ko)
|
1997-04-07 |
2008-11-25 |
제넨테크, 인크. |
항-vegf 항체
|
AU736549B2
(en)
|
1997-05-21 |
2001-08-02 |
Merck Patent Gesellschaft Mit Beschrankter Haftung |
Method for the production of non-immunogenic proteins
|
CO4940418A1
(es)
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
EP1015616A2
(en)
|
1997-09-19 |
2000-07-05 |
Dana Farber Cancer Institute, Inc. |
Intrabody-mediated control of immune reactions
|
GB9722131D0
(en)
*
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
JP2001520039A
(ja)
|
1997-10-21 |
2001-10-30 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒト腫瘍壊死因子レセプター様タンパク質、tr11,tr11sv1およびtr11sv2
|
WO1999040196A1
(en)
|
1998-02-09 |
1999-08-12 |
Genentech, Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
DE19835635C2
(de)
|
1998-08-06 |
2000-05-25 |
Knorr Bremse Systeme |
Relaisventil für Druckluftbremssysteme von Schienenfahrzeugen
|
US6818749B1
(en)
|
1998-10-31 |
2004-11-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Variants of humanized anti carcinoma monoclonal antibody cc49
|
US7888477B2
(en)
|
1998-12-17 |
2011-02-15 |
Corixa Corporation |
Ovarian cancer-associated antibodies and kits
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
ES2295040T3
(es)
|
1999-07-12 |
2008-04-16 |
Genentech, Inc. |
Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
|
DK1210428T3
(en)
|
1999-08-23 |
2015-06-15 |
Dana Farber Cancer Inst Inc |
PD-1, a receptor for B7-4 AND USE THEREOF
|
PT1242438E
(pt)
|
1999-12-29 |
2007-02-28 |
Immunogen Inc |
Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
EP1975182A1
(en)
|
2000-02-01 |
2008-10-01 |
PanGenetics B.V. |
CD40-binding APC-activating molecules
|
AU2001259215A1
(en)
|
2000-04-28 |
2001-11-12 |
La Jolla Institute For Allergy And Immunology |
Human anti-cd40 antibodies and methods of making and using same
|
US6696620B2
(en)
|
2000-05-02 |
2004-02-24 |
Epicyte Pharmaceutical, Inc. |
Immunoglobulin binding protein arrays in eukaryotic cells
|
DE60132699T2
(de)
|
2000-06-06 |
2009-01-29 |
Bristol-Myers Squibb Co. |
Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung
|
PL208113B1
(pl)
*
|
2000-06-22 |
2011-03-31 |
Genentech Inc |
Agonistyczne przeciwciało monoklonalne anty-trkC, mysie agonistyczne przeciwciało monoklonalne, ludzkie agonistyczne przeciwciało monoklonalne, wyizolowana cząsteczka kwasu nukleinowego kodująca mysie agonistyczne przeciwciało monoklonalne, wyizolowana cząsteczka kwasu nukleinowego kodująca ludzkie przeciwciało anty-trkC, cząsteczka kwasu nukleinowego, linia komórek gospodarza, linia komórek hybrydomy, przeciwciało wytwarzane przez tę linię komórek hybrydomy, wyizolowana cząsteczka kwasu nukleinowego i wektor zawierający tę cząsteczkę kwasu nukleinowego, przeciwciało, polipeptyd, kompozycja
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
EP1354034B8
(en)
|
2000-11-30 |
2008-06-18 |
Medarex, Inc. |
Transgenic transchromosomal rodents for making human antibodies
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
DE60231475D1
(de)
|
2001-01-12 |
2009-04-23 |
Molecules Of Man Ab |
Materialien und methoden zur behandlung von hepatitis c
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
US7667004B2
(en)
*
|
2001-04-17 |
2010-02-23 |
Abmaxis, Inc. |
Humanized antibodies against vascular endothelial growth factor
|
MXPA05000511A
(es)
|
2001-07-12 |
2005-09-30 |
Jefferson Foote |
Anticuepros super humanizados.
|
US20030226155A1
(en)
|
2001-08-30 |
2003-12-04 |
Biorexis Pharmaceutical Corporation |
Modified transferrin-antibody fusion proteins
|
US20040142325A1
(en)
*
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
TWI302836B
(en)
|
2001-10-30 |
2008-11-11 |
Novartis Ag |
Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
PT1478648E
(pt)
|
2002-02-01 |
2014-07-15 |
Ariad Pharma Inc |
Compostos contendo fósforo e suas utilizações
|
DK3000810T3
(en)
|
2002-03-13 |
2017-10-16 |
Array Biopharma Inc |
N3-ALKYLED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR
|
DE60317677T2
(de)
|
2002-06-13 |
2008-10-30 |
Crucell Holland B.V. |
Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
|
WO2007001459A2
(en)
|
2004-11-15 |
2007-01-04 |
Washington University |
Compositions and methods for modulating lymphocyte activity
|
US8546541B2
(en)
|
2002-06-20 |
2013-10-01 |
Washington University |
Compositions and methods for modulating lymphocyte activity
|
HUE10161767T1
(hu)
|
2002-07-03 |
2019-03-28 |
Ono Pharmaceutical Co |
Immunpotenciáló kompozíciók, amelyek anti-PD-L1 antitesteket tartalmaznak
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
US20040047858A1
(en)
|
2002-09-11 |
2004-03-11 |
Blumberg Richard S. |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
|
WO2004039394A1
(en)
|
2002-10-25 |
2004-05-13 |
Genentech, Inc. |
Novel composition and methods for the treatment of immune related diseases
|
ATE466885T1
(de)
|
2002-11-15 |
2010-05-15 |
Novartis Vaccines & Diagnostic |
Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
|
US7488802B2
(en)
|
2002-12-23 |
2009-02-10 |
Wyeth |
Antibodies against PD-1
|
PT1611112E
(pt)
|
2003-02-11 |
2012-11-02 |
Cancer Rec Tech Ltd |
Compostos de isoxazole como inibidores de proteínas de choque térmico
|
EP1592713A2
(en)
|
2003-02-13 |
2005-11-09 |
Pharmacia Corporation |
Antibodies to c-met for the treatment of cancers
|
US20070048740A1
(en)
*
|
2003-02-14 |
2007-03-01 |
Research Association For Biotechnology |
Full-length cDNA
|
US20050009136A1
(en)
|
2003-02-19 |
2005-01-13 |
Dyax Corporation |
PAPP-A ligands
|
RU2339715C2
(ru)
*
|
2003-04-17 |
2008-11-27 |
Сайтек Текнолоджи Корп. |
Композиция и способ экстракции растворителем металлов с использованием альдоксимных или кетоксимных экстрагентов
|
US20050025763A1
(en)
*
|
2003-05-08 |
2005-02-03 |
Protein Design Laboratories, Inc. |
Therapeutic use of anti-CS1 antibodies
|
BRPI0410785A
(pt)
|
2003-05-23 |
2006-06-20 |
Wyeth Corp |
molécula de ácido nucleico isolada, célula hospedeira, animal transgênico não humano, proteìna isolada, oligonucleotìdeo anti-sentido, molécula de sirna, anticorpo isolado, métodos de triagem quanto aos compostos de teste capazes de inibir, de intensificar ou imitar a interação do gitrl com o gitr, para diagnosticar doenças, para tratar um paciente em risco ou diagnosticado com uma doença, para induzir e para inibir a proliferação de uma população celular contendo células t efetoras, de bloquear a supressão e de supressão de uma população celular que inclua células t efetoras na presença de células t reguladoras cd4+cd25+, e para tratar uma doença, composição farmacêutica, e, adjuvante de vacina
|
KR20200034817A
(ko)
|
2003-05-30 |
2020-03-31 |
제넨테크, 인크. |
항-vegf 항체를 사용한 치료
|
AU2004253630B2
(en)
|
2003-07-02 |
2010-11-25 |
Innate Pharma S.A.S. |
Methods for the production and cytotoxicity evaluation of KIR2DL NK-receptor antibodies
|
WO2005007190A1
(en)
|
2003-07-11 |
2005-01-27 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
JP2007509185A
(ja)
|
2003-10-27 |
2007-04-12 |
ノバルティス アクチエンゲゼルシャフト |
βアミロイド産生および/または凝集と関係がある神経障害および血管障害の処置のためのインドリル−ピロールジオン誘導体
|
NZ547633A
(en)
|
2003-11-06 |
2010-08-27 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
CA2545166A1
(en)
|
2003-11-11 |
2005-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Humanized anti-cd47 antibody
|
AU2004293180B2
(en)
|
2003-11-28 |
2011-09-15 |
Astrazeneca Ab |
Antibodies binding to a C-terminal fragment of Apolipoprotein E
|
EP1692318A4
(en)
|
2003-12-02 |
2008-04-02 |
Genzyme Corp |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
|
EP1711495A2
(en)
|
2004-01-23 |
2006-10-18 |
Amgen Inc. |
Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
|
EP1786463A4
(en)
|
2004-03-26 |
2009-05-20 |
Human Genome Sciences Inc |
ANTIBODY AGAINST NOGO RECEPTOR
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
USRE44638E1
(en)
|
2004-05-13 |
2013-12-10 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
WO2006083289A2
(en)
|
2004-06-04 |
2006-08-10 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
US7378423B2
(en)
|
2004-06-11 |
2008-05-27 |
Japan Tobacco Inc. |
Pyrimidine compound and medical use thereof
|
CA2727841A1
(en)
|
2004-06-11 |
2005-12-22 |
Japan Tobacco Inc. |
5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido [2, 3-d] pyrimidine derivatives and related compounds
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
US20060009360A1
(en)
|
2004-06-25 |
2006-01-12 |
Robert Pifer |
New adjuvant composition
|
US20060099203A1
(en)
|
2004-11-05 |
2006-05-11 |
Pease Larry R |
B7-DC binding antibody
|
JP2008511337A
(ja)
|
2004-09-02 |
2008-04-17 |
ジェネンテック・インコーポレーテッド |
ヘテロ多量体分子
|
CA2586313C
(en)
|
2004-11-10 |
2016-03-08 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
CN101128485B
(zh)
*
|
2005-01-07 |
2012-09-26 |
莱克康制药公司 |
针对血管生成素样蛋白4(angptl4)的单克隆抗体
|
EP1856291A4
(en)
*
|
2005-03-04 |
2009-04-01 |
Verenium Corp |
NUCLEIC ACIDS AND PROTEINS, AND METHODS OF MAKING AND USING SAME
|
EP2336323A3
(en)
|
2005-03-25 |
2012-05-23 |
National Research Council Of Canada |
Method for isolation of soluble polypeptides
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
AU2006232287B2
(en)
|
2005-03-31 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
CA3151350A1
(en)
|
2005-05-09 |
2006-11-16 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
MX2007013977A
(es)
|
2005-05-10 |
2008-02-05 |
Incyte Corp |
Moduladores de 2,3-dioxigenasa indolamina y metodos de uso de los mismos.
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
PL1885399T3
(pl)
|
2005-05-26 |
2011-04-29 |
Seattle Genetics Inc |
Humanizowane przeciwciała anty-CD40 i sposoby ich stosowania
|
LT2397156T
(lt)
|
2005-06-08 |
2017-02-27 |
Dana-Farber Cancer Institute, Inc. |
Būdai ir kompozicijos, skirti nuolatinių infekcijų ir vėžio gydymui inhibuojant užprogramuotos ląstelės mirties-1 (pd-1) kelią
|
JP2006345852A
(ja)
*
|
2005-06-16 |
2006-12-28 |
Virxsys Corp |
抗体複合体
|
DE102005028778A1
(de)
|
2005-06-22 |
2006-12-28 |
SUNJÜT Deutschland GmbH |
Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
|
EA019344B1
(ru)
|
2005-07-01 |
2014-03-31 |
МЕДАРЕКС, Эл.Эл.Си. |
Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
|
JP4557003B2
(ja)
|
2005-07-01 |
2010-10-06 |
株式会社村田製作所 |
多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート
|
UA102667C2
(uk)
|
2005-07-18 |
2013-08-12 |
Емджен Інк. |
Людське нейтралізуюче антитіло проти в7rp1
|
PE20070335A1
(es)
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Benzimidazoles sustituidos y metodos para su preparacion
|
PL1931710T3
(pl)
|
2005-08-31 |
2017-06-30 |
Merck Sharp & Dohme Corp. |
Przeciwciała anty-il-23 skonstruowane techniką inżynierii genetycznej
|
US8609816B2
(en)
|
2005-12-08 |
2013-12-17 |
Medarex, L.L.C. |
Human monoclonal antibodies to O8E
|
SI2455382T1
(sl)
|
2005-12-13 |
2017-03-31 |
Incyte Holdings Corporation |
S heteroarilom substituirani pirolo(2,3b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janus kinaze
|
WO2007133822A1
(en)
|
2006-01-19 |
2007-11-22 |
Genzyme Corporation |
Gitr antibodies for the treatment of cancer
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
KR20080096827A
(ko)
|
2006-02-15 |
2008-11-03 |
임클론 시스템즈 인코포레이티드 |
항체 제제
|
AU2007229698B9
(en)
|
2006-03-24 |
2012-11-08 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
UA93548C2
(uk)
|
2006-05-05 |
2011-02-25 |
Айерем Елелсі |
Сполуки та композиції як модулятори хеджхогівського сигнального шляху
|
EP2035456A1
(en)
|
2006-06-22 |
2009-03-18 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
PE20110224A1
(es)
|
2006-08-02 |
2011-04-05 |
Novartis Ag |
PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
|
GEP20125612B
(en)
|
2006-08-18 |
2012-08-27 |
Novartis Ag |
Prlr-specific antibody and usage thereof
|
ATE531720T1
(de)
|
2006-08-21 |
2011-11-15 |
Genentech Inc |
Aza-benzofuranylverbindungen und anwendungsverfahren dafür
|
EP2074147B1
(en)
*
|
2006-09-29 |
2012-03-21 |
F. Hoffmann-La Roche AG |
Antibodies against ccr5 and uses thereof
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
MX2009005189A
(es)
|
2006-11-15 |
2009-06-30 |
Medarex Inc |
Anticuerpos humanos monoclonales para btla y metodos de uso.
|
EA017405B9
(ru)
|
2006-12-08 |
2014-05-30 |
АйАрЭм ЭлЭлСи |
Соединения и композиции в качестве ингибиторов протеинкиназы
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
CA2673659A1
(en)
|
2006-12-27 |
2008-07-10 |
The Johns Hopkins University |
Methods of detecting and diagnosing inflamatory responses and disorders by determining the level of soluble b7-h4
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
DK2175884T3
(en)
|
2007-07-12 |
2016-09-26 |
Gitr Inc |
Combination USING GITR BINDING MOLECULES
|
KR20100058509A
(ko)
|
2007-07-31 |
2010-06-03 |
메디뮨 엘엘씨 |
다중특이적 에피토프 결합 단백질 및 이의 용도
|
US9243052B2
(en)
|
2007-08-17 |
2016-01-26 |
Daniel Olive |
Method for treating and diagnosing hematologic malignancies
|
US8748356B2
(en)
|
2007-10-19 |
2014-06-10 |
Janssen Biotech, Inc. |
Methods for use in human-adapting monoclonal antibodies
|
SI2207808T1
(sl)
|
2007-11-02 |
2013-09-30 |
Novartis Ag |
Izboljšane Nogo-A vezavne molekule in njihova farmacevtska uporaba
|
EP2851374B1
(en)
|
2007-12-14 |
2017-05-03 |
Bristol-Myers Squibb Company |
Binding molecules to the human OX40 receptor
|
CN101970730A
(zh)
|
2007-12-19 |
2011-02-09 |
森托科尔奥索生物科技公司 |
通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法
|
DK2690101T3
(en)
|
2007-12-19 |
2015-09-28 |
Genentech Inc |
5-anilinoimidazopyridiner and methods of using
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤および使用方法
|
PE20091628A1
(es)
|
2008-03-19 |
2009-11-19 |
Novartis Ag |
Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
|
FR2929946B1
(fr)
|
2008-04-11 |
2010-05-28 |
Pf Medicament |
Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
|
WO2009134389A2
(en)
|
2008-05-01 |
2009-11-05 |
Gtc Biotherapeutics, Inc. |
An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
|
PE20100087A1
(es)
|
2008-06-25 |
2010-02-08 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa
|
CA2729810A1
(en)
|
2008-07-02 |
2010-01-07 |
Emergent Product Development Seattle, Llc |
Tgf-.beta. antagonist multi-target binding proteins
|
NZ590258A
(en)
|
2008-07-08 |
2013-10-25 |
Intellikine Llc |
Kinase inhibitors and methods of use
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
WO2010017103A2
(en)
|
2008-08-04 |
2010-02-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Fully human anti-human nkg2d monoclonal antibodies
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
BRPI0917791B1
(pt)
|
2008-08-22 |
2022-03-22 |
Novartis Ag |
Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
|
US8329732B2
(en)
|
2008-09-02 |
2012-12-11 |
Novartis Ag |
Kinase inhibitors and methods of their use
|
UA104147C2
(uk)
|
2008-09-10 |
2014-01-10 |
Новартис Аг |
Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
|
EP2342229A1
(en)
|
2008-09-12 |
2011-07-13 |
ISIS Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
WO2010029434A1
(en)
|
2008-09-12 |
2010-03-18 |
Isis Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
WO2010030002A1
(ja)
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
外来性gitrリガンド発現細胞
|
WO2010036380A1
(en)
|
2008-09-26 |
2010-04-01 |
Intellikine, Inc. |
Heterocyclic kinase inhibitors
|
WO2010036959A2
(en)
|
2008-09-26 |
2010-04-01 |
Dana-Farber Cancer Institute |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
|
KR101050829B1
(ko)
|
2008-10-02 |
2011-07-20 |
서울대학교산학협력단 |
항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제
|
EP2347038A4
(en)
|
2008-10-14 |
2013-06-12 |
Janssen Biotech Inc |
METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
|
JO3096B1
(ar)
*
|
2008-11-07 |
2017-03-15 |
Imclone Llc |
الأجسام المضادة لمستقبل ii مضاد tgfb
|
CA2744937C
(en)
|
2008-11-28 |
2017-02-28 |
Novartis Ag |
Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
US20110268741A1
(en)
|
2009-01-05 |
2011-11-03 |
The Johns Hopkins University |
Immunotherapy for Contact Dermatitis Using Co-Signal Regulation
|
WO2010083178A1
(en)
*
|
2009-01-16 |
2010-07-22 |
Monsanto Technology Llc |
Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
|
EP2210903A1
(en)
|
2009-01-21 |
2010-07-28 |
Monoclonal Antibodies Therapeutics |
Anti-CD160 monoclonal antibodies and uses thereof
|
EP3192811A1
(en)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
UA103918C2
(en)
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
|
AR075989A1
(es)
*
|
2009-04-10 |
2011-05-11 |
Lilly Co Eli |
Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
|
AU2010245011B2
(en)
|
2009-04-27 |
2015-09-03 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
ES2668874T3
(es)
|
2009-04-30 |
2018-05-22 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Anticuerpos anti-CEACAM1 y métodos de uso de los mismos
|
RU2420587C2
(ru)
|
2009-06-25 |
2011-06-10 |
Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА И Fab, СВЯЗЫВАЮЩИЕСЯ С АНТИГЕНОМ F1 ИЗ Yersinia pestis, И СПОСОБ ИХ ПОЛУЧЕНИЯ С ИСПОЛЬЗОВАНИЕМ ДРОЖЖЕЙ
|
PT2445903E
(pt)
|
2009-06-26 |
2014-07-08 |
Novartis Ag |
Derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp17
|
EP2459594A1
(en)
|
2009-07-31 |
2012-06-06 |
N.V. Organon |
Fully human antibodies to btla
|
AR077975A1
(es)
|
2009-08-28 |
2011-10-05 |
Irm Llc |
Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
|
US8709424B2
(en)
|
2009-09-03 |
2014-04-29 |
Merck Sharp & Dohme Corp. |
Anti-GITR antibodies
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
LT3279215T
(lt)
*
|
2009-11-24 |
2020-04-10 |
Medimmune Limited |
Tiksliniai surišantys agentai prieš b7-h1
|
BR112012013038A2
(pt)
|
2009-11-30 |
2016-10-25 |
Janssen Biotech Inc |
mutantes fc de anticorpo com funções efetoras ablacionadas
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
NZ600820A
(en)
|
2009-12-29 |
2014-12-24 |
Emergent Product Dev Seattle |
Heterodimer binding proteins and uses thereof
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
WO2011103426A2
(en)
*
|
2010-02-19 |
2011-08-25 |
The Board Of Regents Of The University Of Oklahoma |
Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
|
CA2791658C
(en)
|
2010-03-04 |
2019-10-01 |
Macrogenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
US8993731B2
(en)
|
2010-03-11 |
2015-03-31 |
Ucb Biopharma Sprl |
PD-1 antibody
|
AU2011244282A1
(en)
|
2010-04-20 |
2012-11-15 |
Genmab A/S |
Heterodimeric antibody Fc-containing proteins and methods for production thereof
|
EP2566514A4
(en)
*
|
2010-05-03 |
2013-11-27 |
Abbvie Inc |
METHODS OF INHIBITING FIBROSIS WITH ANTI-PAI-1 ANTIBODIES
|
HUE031778T2
(en)
*
|
2010-05-14 |
2017-07-28 |
Univ Leland Stanford Junior |
Humanized and chimeric monoclonal antibodies against CD47
|
ES2682078T3
(es)
*
|
2010-06-11 |
2018-09-18 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpo anti-TIM-3
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
US8735551B2
(en)
|
2010-08-20 |
2014-05-27 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
EA029793B1
(ru)
|
2010-08-23 |
2018-05-31 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Антитела к ох40 и способы их применения
|
SG188313A1
(en)
|
2010-09-09 |
2013-04-30 |
Pfizer |
4-1bb binding molecules
|
EP2621950A4
(en)
*
|
2010-09-27 |
2015-09-02 |
Janssen Biotech Inc |
ANTIBODIES FOR BINDING HUMAN COLLAGEN II
|
WO2012061448A1
(en)
|
2010-11-04 |
2012-05-10 |
Boehringer Ingelheim International Gmbh |
Anti-il-23 antibodies
|
JP6167040B2
(ja)
|
2010-11-05 |
2017-07-19 |
ザイムワークス,インコーポレイテッド |
Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
|
DE102010052101A1
(de)
|
2010-11-20 |
2012-05-24 |
Schaeffler Technologies Gmbh & Co. Kg |
Lagervorrichtung mit einem Fanglager
|
GB201020995D0
(en)
|
2010-12-10 |
2011-01-26 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
CN111246575B
(zh)
|
2011-03-31 |
2020-12-25 |
华为技术有限公司 |
时分双工***中子帧配置的方法、基站及用户设备
|
US9220776B2
(en)
|
2011-03-31 |
2015-12-29 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
|
LT2699264T
(lt)
|
2011-04-20 |
2018-07-10 |
Medimmune, Llc |
Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1
|
WO2012145568A1
(en)
|
2011-04-21 |
2012-10-26 |
Albert Einstein College Of Medicine Of Yeshiva University |
Antibodies to human b7x for treatment of metastatic cancer
|
CA2840170A1
(en)
|
2011-06-21 |
2012-12-27 |
The Johns Hopkins University |
Focused radiation for augmenting immune-based therapies against neoplasms
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
KR20190133790A
(ko)
|
2011-08-01 |
2019-12-03 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
|
KR101685262B1
(ko)
|
2011-08-23 |
2016-12-21 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
항-ox40 항체 및 이의 사용 방법
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
KR20140074330A
(ko)
|
2011-09-07 |
2014-06-17 |
도이체스 크렙스포르슝스첸트룸 |
천연 ahr 리간드-의존성 암을 치료 및/또는 예방하기 위한 수단 및 방법
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
ES2899956T3
(es)
|
2011-11-04 |
2022-03-15 |
Zymeworks Inc |
Diseño de anticuerpo heterodimérico estable con mutaciones en el dominio Fc
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
EA201492007A1
(ru)
|
2012-05-15 |
2015-03-31 |
Новартис Аг |
Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
|
CN113967253A
(zh)
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
AU2013261127B2
(en)
|
2012-05-15 |
2015-03-12 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
|
CN104334529B
(zh)
|
2012-05-15 |
2017-03-15 |
诺华股份有限公司 |
用于抑制abl1、abl2和bcr‑abl1的活性的化合物和组合物
|
EP2858988B1
(en)
|
2012-05-15 |
2018-02-28 |
Novartis AG |
Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
|
JP2015520192A
(ja)
|
2012-06-06 |
2015-07-16 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Hippo経路を調節する結合剤およびその使用
|
JO3300B1
(ar)
|
2012-06-06 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات لتعديل نشاط egfr
|
JP2015532587A
(ja)
*
|
2012-06-21 |
2015-11-12 |
コンピュゲン エルティーディー. |
Lsr抗体およびがんの治療のためのその使用
|
EP2879709B1
(en)
|
2012-07-31 |
2020-01-08 |
The Brigham and Women's Hospital, Inc. |
Modulation of the immune response
|
US20140227250A1
(en)
|
2012-08-23 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to tslp
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
CN110066335B
(zh)
|
2012-10-30 |
2024-04-05 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
US20150283136A1
(en)
|
2012-11-08 |
2015-10-08 |
Novartis Ag |
Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
|
PT2922872T
(pt)
|
2012-11-21 |
2019-01-18 |
Janssen Biotech Inc |
Anticorpos biespecíficos de egfr/c-met
|
AU2013352406A1
(en)
|
2012-11-28 |
2015-06-04 |
Novartis Ag |
Combination therapy
|
SG11201504764SA
(en)
|
2012-12-19 |
2015-07-30 |
Amplimmune Inc |
Anti-human b7-h4 antibodies and their uses
|
CN105229026B
(zh)
|
2013-01-10 |
2021-07-30 |
根马布私人有限公司 |
人类IgG1 FC区变体及其用途
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
AP2015008707A0
(en)
|
2013-03-14 |
2015-09-30 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
WO2014159764A1
(en)
|
2013-03-14 |
2014-10-02 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
CA2902865A1
(en)
|
2013-03-14 |
2014-10-02 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
LT2970473T
(lt)
|
2013-03-14 |
2017-10-25 |
Bristol-Myers Squibb Company |
Dr5 agonisto ir anti-pd-1 antagonisto derinys ir naudojimo būdai
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
WO2014144080A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
RS57791B1
(sr)
|
2013-03-15 |
2018-12-31 |
Janssen Biotech Inc |
Postupci dobijanja za kontrolu sadržaja c-terminalnog lizina, galaktoze i sijalinske kiseline u rekombinovanim proteinima
|
LT2976361T
(lt)
|
2013-03-18 |
2018-10-25 |
Biocerox Products B.V. |
Humanizuoti antikūnai prieš receptorių cd134 (ox40) ir jų naudojimas
|
KR102243062B1
(ko)
|
2013-05-02 |
2021-04-21 |
아납티스바이오, 아이엔씨. |
예정된 사멸-1에 대한 항체
|
JP6603209B2
(ja)
*
|
2013-05-10 |
2019-11-06 |
ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ |
ソルターゼ(Sortase)を用いた生存細胞のタンパク質修飾
|
US10005839B2
(en)
|
2013-05-17 |
2018-06-26 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antagonist of the BTLA/HVEM interaction for use in therapy
|
US9676853B2
(en)
|
2013-05-31 |
2017-06-13 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-1
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
JP6636920B2
(ja)
|
2013-07-16 |
2020-01-29 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト及びtigit阻害剤を使用するがんの治療方法
|
CA2918780C
(en)
|
2013-07-24 |
2023-08-08 |
Dana-Farber Cancer Institute, Inc. |
Anti-galectin-1 (gal1) monoclonal antibodies and fragments thereof for neutralizing gal1
|
NZ717534A
(en)
|
2013-08-22 |
2022-04-29 |
Council Queensland Inst Medical Res |
Immunoreceptor modulation for treating cancer and viral infections
|
WO2015036394A1
(en)
|
2013-09-10 |
2015-03-19 |
Medimmune Limited |
Antibodies against pd-1 and uses thereof
|
BR112016005408B1
(pt)
|
2013-09-13 |
2023-03-21 |
Beigene Switzerland Gmbh |
Anticorpos anti-pd1, f(ab) ou f(ab)2 e uso referido anticorpo para tratamento de cancer ou infecção viral
|
CN104558177B
(zh)
|
2013-10-25 |
2020-02-18 |
苏州思坦维生物技术股份有限公司 |
拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
|
MY184154A
(en)
|
2013-12-12 |
2021-03-23 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
CA2932515C
(en)
|
2013-12-20 |
2023-08-01 |
Intervet International B.V. |
Caninized antibodies
|
US9456612B2
(en)
|
2013-12-26 |
2016-10-04 |
Zimplistic Pte. Ltd. |
Dry flour dispensing apparatus and using the same for a food preparation appliance
|
CN103721255A
(zh)
*
|
2014-01-07 |
2014-04-16 |
苏州大学 |
共同阻断pd-1和tim-3信号通路在抗胃癌治疗中的用途
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
JP6868394B2
(ja)
|
2014-05-16 |
2021-05-12 |
ファイザー・インク |
二重特異性抗体
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
JP6279733B2
(ja)
|
2014-07-09 |
2018-02-14 |
日本全薬工業株式会社 |
抗イヌpd−1抗体又は抗イヌpd−l1抗体
|
US10428146B2
(en)
|
2014-07-22 |
2019-10-01 |
Cb Therapeutics, Inc. |
Anti PD-1 antibodies
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
EP3177644B1
(en)
|
2014-08-05 |
2020-10-07 |
Mabquest SA |
Immunological reagents binding to pd-1
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
US10822414B2
(en)
|
2014-11-11 |
2020-11-03 |
Sutro Biopharma, Inc. |
Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
US10239942B2
(en)
|
2014-12-22 |
2019-03-26 |
Pd-1 Acquisition Group, Llc |
Anti-PD-1 antibodies
|
CN105061597B
(zh)
|
2015-06-09 |
2016-04-27 |
北京东方百泰生物科技有限公司 |
一种抗pd-1的单克隆抗体及其获得方法
|
CN108337890B
(zh)
|
2015-06-23 |
2021-10-15 |
纪念斯隆-凯特琳癌症中心 |
新型pd-1免疫调节剂
|
US20170044265A1
(en)
*
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
MX2018000261A
(es)
*
|
2015-06-24 |
2018-03-08 |
Janssen Biotech Inc |
Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38.
|
MA42447A
(fr)
|
2015-07-13 |
2018-05-23 |
Cytomx Therapeutics Inc |
Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
|
CN106699888B
(zh)
|
2015-07-28 |
2020-11-06 |
上海昀怡健康科技发展有限公司 |
一种pd-1抗体及其制备方法和应用
|
CN114773475B
(zh)
|
2015-07-30 |
2024-01-12 |
宏观基因有限公司 |
Pd-1结合分子和其使用方法
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
WO2017024515A1
(en)
|
2015-08-11 |
2017-02-16 |
Wuxi Biologics (Cayman) Inc. |
Novel anti-pd-1 antibodies
|
AU2016317915B2
(en)
|
2015-09-01 |
2021-02-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
MX2018003306A
(es)
|
2015-09-28 |
2018-05-16 |
Suzhou Suncadia Biopharmaceuticals Co Ltd |
Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina.
|
JP6952028B2
(ja)
|
2015-09-29 |
2021-10-20 |
シャンハイ チャンジアン バイオテクノロジー カンパニー リミテッド |
Pd−1抗体およびその使用
|
EA201890790A1
(ru)
|
2015-09-29 |
2018-10-31 |
Селджин Корпорейшн |
Связывающие pd-1 белки и способы их применения
|
PE20181092A1
(es)
|
2015-10-02 |
2018-07-09 |
Hoffmann La Roche |
Anticuerpos anti-pd1 y metodos de uso
|
PL3368572T3
(pl)
|
2015-10-02 |
2022-09-12 |
Symphogen A/S |
Przeciwciała anty-PD-1 oraz kompozycje
|
PT3356411T
(pt)
|
2015-10-02 |
2021-08-30 |
Hoffmann La Roche |
Anticorpos biespecíficos específicos para pd1 e tim3
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
CN106632674B
(zh)
|
2015-10-30 |
2018-11-16 |
泽达生物医药有限公司 |
一种抗pd-1单克隆抗体、其药物组合物及其用途
|
EP4046655A1
(en)
|
2015-11-03 |
2022-08-24 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and their uses
|
AU2016355568A1
(en)
|
2015-11-18 |
2018-06-21 |
Merck Sharp & Dohme Llc |
PD1/CTLA4 Binders
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
抗pd-1抗体及其治疗用途
|
MA43859A
(fr)
|
2016-01-11 |
2018-11-21 |
Novartis Ag |
Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
WO2018026248A1
(ko)
|
2016-08-05 |
2018-02-08 |
주식회사 와이바이오로직스 |
프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도
|
WO2018027524A1
(en)
|
2016-08-09 |
2018-02-15 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibody formulation
|
CN106977602B
(zh)
|
2016-08-23 |
2018-09-25 |
中山康方生物医药有限公司 |
一种抗pd1单克隆抗体、其药物组合物及其用途
|
TN2019000081A1
(en)
|
2016-09-14 |
2020-07-15 |
Beijing hanmi pharm co ltd |
Antibody specifically binding to pd-1 and functional fragment thereof
|
BR112019004998A2
(pt)
|
2016-09-14 |
2019-06-04 |
Abbvie Biotherapeutics Inc |
anticorpos anti-pd-1(cd279)
|
MX2019003058A
(es)
|
2016-09-21 |
2019-11-28 |
Cstone Pharmaceuticals |
Anticuerpos monoclonales novedosos para muerte programada 1 (pd-1).
|
DE102017211373A1
(de)
|
2017-07-04 |
2019-01-10 |
Continental Automotive Gmbh |
Induktive Ladevorrichtung für ein elektrisch antreibbares Kraftfahrzeug und Betriebsverfahren für die Ladevorrichtung
|